Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (12,958,711)	$ (14,286,756)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	22,318	7,052
Stockbased compensation	489,436	444,459
Issuance of common stock to consultant	17,435
Foreign currency (gain) loss	(71,800)	38,926
Changes in operating assets and liabilities:
Prepaid expenses and other current and noncurrent assets	(96,674)	451,994
Accounts payable	(314,207)	827,463
Accrued expenses	(115,541)	(189,720)
Deferred grant revenue	(528,974)	528,974
Net cash used in operating activities	(13,556,718)	(12,177,608)
Cash flows from investing activities:
Purchases of property and equipment	(15,478)	(93,093)
Net cash used in investing activities	(15,478)	(93,093)
Cash flows from financing activities:
Proceeds from issuance of common stock	16,140,356	5,788,918
Common stock issuance costs	(1,318,461)	(648,928)
Net cash provided by financing activities	14,821,895	5,139,990
Change in cash, cash equivalents and restricted cash	1,249,699	(7,130,711)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(7,181)	(8,399)
Cash, cash equivalents and restricted cash-beginning of year	21,647,537	28,786,647
Cash, cash equivalents and restricted cash-end of period	22,890,055	21,647,537
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	22,849,885	21,606,820
Restricted cash	40,170	40,717
Total cash, cash equivalents and restricted cash	$ 22,890,055	$ 21,647,537